Re: Farmas USA
OCAT
Artículo en SA
Since the announcement of the offer, shares have consistently traded within $.10 of the tender price, with the exception a single trading day, indicating a high expected likelihood of completion. However, an online campaign by angry shareholders to turn down the offer has so far been successful and December 17th came and went without Ocata and Astellas able to convince more than 50% of shareholders to accept the offer. Instead of walking away, Astellas decided to extend the $8.50 tender deadline to January 21, 2016.
SEC Disclosure Reveals that Company Has Hired Outside Firm to Push Acquisition.
if the offer falls apart, a management shakeup is likely to be in the cards. The question then becomes whether the remaining shareholders will end up regretting their decision or see a better outcome down the road. Only time will tell.
«Después de nada, o después de todo/ supe que todo no era más que nada.»